Log in to search using one of your social media accounts:

 

A naturalistic comparison of methylphenidate and risperidone monotherapy in drug-naive youth with attention-deficit/hyperactivity disorder comorbid with oppositional defiant disorder and aggression - Masi G, Manfredi A, Nieri G, Muratori P, Pfanner C, Milone A.
BACKGROUND/PURPOSE: Attention-deficit/hyperactivity disorder (ADHD) and oppositional defiant disorder (ODD) are frequently co-occurring in youth, but data about the pharmacological management of this comorbidity are scarce, especially when impulsive aggres... (Source: SafetyLit)
Source: SafetyLit - August 25, 2017 Category: International Medicine & Public Health Tags: Age: Adolescents Source Type: news

methylphenidate hydrochloride (Quillivant XR)
Title: methylphenidate hydrochloride (Quillivant XR)Category: MedicationsCreated: 7/24/2014 12:00:00 AMLast Editorial Review: 8/8/2017 12:00:00 AM (Source: MedicineNet Kids Health General)
Source: MedicineNet Kids Health General - August 8, 2017 Category: Pediatrics Source Type: news

Association of risk of suicide attempts with methylphenidate treatment - Man KKC, Coghill D, Chan EW, Lau WCY, Hollis C, Liddle E, Banaschewski T, McCarthy S, Neubert A, Sayal K, Ip P, Schuemie MJ, Sturkenboom MCJM, Sonuga-Barke E, Buitelaar J, Carucci S, Zuddas A, Kovshoff H, Garas P, Nagy P, Inglis SK, Konrad K, H ├Ąge A, Rosenthal E, Wong ICK.
IMPORTANCE: Patients with attention-deficit/hyperactivity disorder (ADHD) are at an increased risk of attempting suicide. Stimulants, such as methylphenidate hydrochloride, are the most common treatment for ADHD, but the association between their therapeut... (Source: SafetyLit)
Source: SafetyLit - July 29, 2017 Category: International Medicine & Public Health Tags: Alcohol and Other Drugs Source Type: news

Methylphenidate-Suicide Link Doesn't Appear Causal (FREE)
By Amy Orciari Herman Edited by Susan Sadoughi, MD Any link between the ADHD drug methylphenidate and suicide attempts does not appear to be causal, according to an observational study in JAMA Psychiatry.Using a … (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - July 27, 2017 Category: Primary Care Source Type: news

Cotempla XR ODT (Methylphenidate Extended-Release Orally Disintegrating Tablets) - new on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - June 29, 2017 Category: Drugs & Pharmacology Source Type: news

Methylphenidate disintegration from oral formulations for intravenous use by experienced substance users - Bjarnadottir GD, Johannsson M, Magnusson A, Rafnar BO, Sigurdsson E, Steingrimsson S, Asgrimsson V, Snorradottir I, Bragadottir H, Haraldsson HM.
BACKGROUND AND AIMS: Methylphenidate (MPH) is a prescription stimulant used to treat attention-deficit hyperactivity disorder. MPH is currently the preferred substance among most intravenous (i.v.) substance users in Iceland. Four types of MPH preparations... (Source: SafetyLit)
Source: SafetyLit - June 28, 2017 Category: International Medicine & Public Health Tags: Alcohol and Other Drugs Source Type: news

Another extended-release ADHD drug wins FDA nod
Days after Neos Therapeutics (NSDQ:NEOS) nabbed U.S. regulatory approval for its controlled-release formulation of methylphenidate, Shire (NSDQ:SHPG) said it won a nod from the FDA for its long-acting ADHD drug. The drug, Mydayis, is made up of the same active ingredient in Shire’s ADHD treatment Adderall XR – amphetamine – but it is designed to last up to 16 hours. Adderall XR is formulated to control symptoms in patients for up to 12 hours. Get the full story at our sister site, Drug Delivery Business News. The post Another extended-release ADHD drug wins FDA nod appeared first on MassDev...
Source: Mass Device - June 21, 2017 Category: Medical Devices Authors: Sarah Faulkner Tags: Food & Drug Administration (FDA) Neurological Pharmaceuticals Regulatory/Compliance Wall Street Beat neostherapeutics Shire Plc. Source Type: news

Controlled-release ADHD drug wins FDA approval
Neos Therapeutics (NSDQ:NEOS) won FDA approval yesterday for its controlled-release formulation of an old ADHD drug, methylphenidate. The company touts its product, Cotempla XR-ODT, as the 1st methylphenidate tablet designed to release medication over time instead of all at once. Get the full story at our sister site, Drug Delivery Business News. The post Controlled-release ADHD drug wins FDA approval appeared first on MassDevice. (Source: Mass Device)
Source: Mass Device - June 20, 2017 Category: Medical Devices Authors: Sarah Faulkner Tags: Food & Drug Administration (FDA) Neurological Pharmaceuticals Regulatory/Compliance Wall Street Beat neostherapeutics Source Type: news

FDA Clears New Methylphenidate Formulation for ADHD FDA Clears New Methylphenidate Formulation for ADHD
Cotempla XR-ODT is a once-daily extended-release orally disintegrating tablet formulation of methylphenidate for patients aged 6 to 17 years with ADHD.FDA Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 20, 2017 Category: Consumer Health News Tags: Psychiatry News Alert Source Type: news

Neos Therapeutics Announces FDA Approval of Cotempla XR-ODT (methylphenidate) Extended-Release Orally Disintegrating Tablets for the Treatment of ADHD in Patients 6 to 17 Years Old
DALLAS and FORT WORTH, Texas, June 19, 2017 (GLOBE NEWSWIRE) -- Neos Therapeutics, Inc. (Nasdaq:NEOS), a pharmaceutical company focused on developing, manufacturing and commercializing innovative extended-release (XR) products using its proprietary... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - June 19, 2017 Category: Drugs & Pharmacology Source Type: news

The effects of methylphenidate on the neural signatures of sustained attention - Dockree PM, Barnes JJ, Matthews N, Dean AJ, Abe R, Nandam LS, Kelly SP, Bellgrove MA, O'Connell RG.
We examined how MPH influenced known electrophysiological precursors of lapsing attenti... (Source: SafetyLit)
Source: SafetyLit - June 14, 2017 Category: International Medicine & Public Health Tags: Alcohol and Other Drugs Source Type: news

Ritalin LA (Methylphenidate Hydrochloride Extended-Release Capsules) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - June 9, 2017 Category: Drugs & Pharmacology Source Type: news

How Do I Keep My Prescription Stimulant Safe At College?
Discussion Going away to college presents new and exciting opportunities for young adults. It also is an important time for transitioning many adult responsibilities to the young adult too. Keeping safe is important and safety tips for college can be reviewed here. Any medication can be abused. Prescription stimulants are no different. Normally prescription stimulants are used for treatment of attention deficit disorder, narcolepsy and treatment resistant depression. They can help increase alertness, attention, and energy, cognition, learning and memory. However for these reasons and because they are easy to obtain and r...
Source: PediatricEducation.org - June 5, 2017 Category: Pediatrics Authors: pediatriceducationmin Tags: Uncategorized Source Type: news

Methylphenidate Hydrochloride Tablets, USP (New - Discontinuation)
Drug Shortage (Source: FDA Drug Shortages)
Source: FDA Drug Shortages - May 17, 2017 Category: Drugs & Pharmacology Source Type: news

Simulated driving skills evaluation of teenagers with attention deficit hyperactivity disorder before driving lessons - Ratzon NZ, Lunievsky EK, Ashkenasi A, Laks J, Cohen HA.
OBJECTIVE: We evaluated the driving skills of teenagers with attention deficit hyperactivity disorder (ADHD) during simulated driving before starting driving lessons and observed whether methylphenidate (MPH) affected their performance. METHOD: Six... (Source: SafetyLit)
Source: SafetyLit - April 26, 2017 Category: Global & Universal Tags: Age: Adolescents Source Type: news

Suicide attempt with high dose long acting methylphenidate ingestion: a case presentation - Erkuran HO, Cakaloz APB, Onen O, Kutlu A.
Attention Deficit and Hyperactivity Disorder (ADHD) is among the most commonly encountered neurodevelopmental disorders in childhood with its reported worldwide prevalance as 5%. Among the recommended treatment regimens as stimulants, the most frequently a... (Source: SafetyLit)
Source: SafetyLit - April 19, 2017 Category: Global & Universal Tags: Alcohol and Other Drugs Source Type: news

Pharmacological and non-pharmacological treatment of adults with ADHD: a meta-review
In conclusion, while available evidence addressed mainly the efficacy and tolerability of psychostimulants and non-psychostimulants for ADHD core symptoms in the short term, we still need further empirical support for the non-pharmacological and multimodal treatments. A comprehensive evidence-informed hierarchy of ADHD drugs based on their efficacy and tolerability is not yet available but it should be the next research priority in the field. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - March 16, 2017 Category: Consumer Health News Source Type: news

Methylphenidate for ADHD in children and adolescents: throwing the baby out with the bathwater.
A recent Cochrane review assessed the efficacy of methylphenidate for attention-deficit/hyperactivity disorder (ADHD) in children and adolescents. Notwithstanding the moderate-to-large effect sizes for ADHD symptom reduction found in the meta-analysis, the authors concluded that the quality of the evidence is low and therefore the true magnitude of these effects remains uncertain. We identified a number of major concerns with the review, in the domains of study inclusion, approaches to quality assessment and interpretation of data relating to serious adverse events as well as of the clinical implications of the reported ef...
Source: Current Awareness Service for Health (CASH) - March 16, 2017 Category: Consumer Health News Source Type: news

Evidence on methylphenidate in children and adolescents with ADHD is in fact of very low quality
Banaschewski and colleagues from the European Attention Deficit Hyperactivity Disorder (ADHD) guideline group make a number of critical comments regarding our systematic review on methylphenidate for children and adolescents with ADHD. In this article, we present our views, showing that our trial selection was not flawed and was undertaken with scientific justification. Similarly, our data collection and interpretation was systematic and correct. We have followed a sound methodology for assessing risk of bias and our conclusions are not misleading. We acknowledge that different researchers might make risk of bias judgments...
Source: Current Awareness Service for Health (CASH) - March 16, 2017 Category: Consumer Health News Source Type: news

Cognitive enhancing drugs can improve chess play, scientists show
The first study to both show and measure the effects of cognitive-enhancing drugs such as modafinil, methylphenidate (best known under the trade name Ritalin), and caffeine, on chess play is being published. Research shows significant cognitive improvements for modafinil and methylphenidate, and may influence how these drugs are used off-label in a range of activities. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - March 6, 2017 Category: Science Source Type: news

The influence of stimulants on performance when playing chess
(Johannes Gutenberg Universitaet Mainz) High-performance tournament chess players can actually enhance the highly complex cognitive functions they require by taking substances such as the CNS stimulant methylphenidate or the wakefulness promoter modafinil and thus win more chess matches -- unless they are under time pressure. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - March 6, 2017 Category: Global & Universal Source Type: news

Scientists show cognitive-enhancing drugs can improve chess play
(European College of Neuropsychopharmacology) The first study to both show and measure the effects of cognitive-enhancing drugs such as modafinil, methylphenidate (best known under the trade name Ritalin), and caffeine, on chess play is being published in the March edition of the peer-reviewed journal European Neuropsychopharmacology. This shows significant cognitive improvements for modafinil and methylphenidate, and may have influence how these drugs are used off-label in a range of activities. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - March 6, 2017 Category: Global & Universal Source Type: news

FDA gives Lannett more time to make its case for ADHD drug
The Food and Drug Administration has decided to give Lannett Co. Inc. more time to show why its generic ADHD drug should be allowed to remain in the market. Back in October, the FDA informed the Northeast Philadelphia generic drug manufacturer that the agency was preparing to withdraw its approval of the company’s Methylphenidate Hydrochloride extended-release tablets, prescribed to treat attention deficit hyperactivity disorder, based in part on re ports by patients that the therapeutics benefits… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - February 22, 2017 Category: Pharmaceuticals Authors: John George Source Type: news

Methylin Chewable Tablets (Methylphenidate HCl Chewable Tablets ) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - January 23, 2017 Category: Drugs & Pharmacology Source Type: news

Aptensio XR (Methylphenidate Hydrochloride Extended-release Capsules ) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - January 23, 2017 Category: Drugs & Pharmacology Source Type: news

Methylin Oral Solution (Methylphenidate HCl Oral Solution 5 mg/5 mL and 10 mg/5 mL) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - January 23, 2017 Category: Drugs & Pharmacology Source Type: news

Ritalin (Methylphenidate Hcl) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - January 20, 2017 Category: Drugs & Pharmacology Source Type: news

Concerta (Methylphenidate Extended-Release Tablets) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - January 20, 2017 Category: Drugs & Pharmacology Source Type: news

Mylan launches new ADHD treatment in US
US-based pharmaceuticals company Mylan has launched the Methylphenidate Hydrochloride Extended-Release Tablets USP in the country for the treatment of patients affected with attention deficit hyperactivity disorder (ADHD). (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - January 3, 2017 Category: Pharmaceuticals Source Type: news

No superiority of treatment with osmotic controlled-release oral delivery system-methylphenidate over short/medium-acting methylphenidate preparations in the rate and timing of injuries in children with attention-deficit/hyperactivity disorder - Golubchik P, Kodesh A, Weizman A.
OBJECTIVES: Methylphenidate (MPH) treatment in patients with attention-deficit/hyperactivity disorder (ADHD) is reported to reduce the risk for injuries. In the present study, the rate and timing of injuries were compared among the various MPH preparations... (Source: SafetyLit)
Source: SafetyLit - December 3, 2016 Category: Global & Universal Tags: Age: Adolescents Source Type: news

ADHD Drug Plus Therapy Improves Cognitive Outcomes In TBI Patients
Study reveals combination of methylphenidate with cognitive-behavioral rehabilitation a promising option for people with persistent cognitive problems following traumatic brain injury (Source: Disabled World)
Source: Disabled World - November 25, 2016 Category: Disability Tags: Traumatic Brain Injury Source Type: news

Adding ADHD drug to therapy improves cognitive outcomes in traumatic brain injury patients
(Indiana University) A combination of the stimulant drug methylphenidate with a process known as cognitive-behavioral rehabilitation is a promising option to help people who suffer from persistent cognitive problems following traumatic brain injury, researchers at Indiana University School of Medicine have reported. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - November 22, 2016 Category: Global & Universal Source Type: news

Metadate ER (Methylphenidate Hydrochloride Extended Release Tablet) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - November 7, 2016 Category: Drugs & Pharmacology Source Type: news

Quillichew ER (Methylphenidate Hydrochloride Extended-release Chewable Tablets) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - October 31, 2016 Category: Drugs & Pharmacology Source Type: news

Methylphenidate Ups Arrhythmia Risk in Kids
The relative risk of CV events with methylphenidate is generally low; however risk of MI may be higher in the early days after initiation. (Source: ConsultantLive)
Source: ConsultantLive - September 20, 2016 Category: Internal Medicine Authors: Veronica Hackethal, MD Tags: ADHD Source Type: news

Daytrana (Methylphenidate Transdermal) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - September 7, 2016 Category: Drugs & Pharmacology Source Type: news

In Klinefelter Syndrome Patients, What are the Common Behavioral Problems?
Discussion Klinefelter syndrome (KS) is a common genetic abnormaly with a prevalence of 1 in ~650 male births. It was first described in 1942 by Dr. Harry Klinefelter. It is associated with at least one extra X chromosome with the most common karyotype (~80% of patients) being 47 XXY. Other karyotypes are seen along with mosaicism. It is believed that although it is very prevalent, only about 25-33% of people with KS are identified. About 10% are identified before puberty with the rest usually identified because of hypogonadism and tall stature especially in teenage years or due to infertility in adulthood. KS is diagnosed...
Source: PediatricEducation.org - August 29, 2016 Category: Pediatrics Authors: pediatriceducationmin Tags: Uncategorized Source Type: news

ADHD Med Linked to Brain Changes in Kids After Stopping ADHD Med Linked to Brain Changes in Kids After Stopping
Children treated with methylphenidate for ADHD show brain changes after discontinuing the drug, suggesting'neurochemical imprinting'on the developing brain, with uncertain long-term consequences.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - August 9, 2016 Category: Consumer Health News Tags: Psychiatry News Source Type: news

Cardiovascular Safety of Methylphenidate Use in ADHDCardiovascular Safety of Methylphenidate Use in ADHD
There is conflicting evidence regarding the cardiac safety of stimulant use, especially in children. Does methylphenidate use in ADHD put children and young people at risk for adverse CV events? British Medical Journal (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - June 24, 2016 Category: Consumer Health News Tags: Pediatrics Journal Article Source Type: news

Ritalin Could Trigger Heart Problems In Children
Ritalin and similar forms of ADHD medication may trigger abnormal heart rhythms and increase heart attack risk in some children soon after they start taking the drug, according to a new study.  This connection was especially true for children who were born with heart disease. According to the study, published in the British medical journal BMJ, kids had an increased risk of heart attack between eight and 56 days after starting methylphenidate, a stimulant most commonly sold as Ritalin, although this heightened risk didn’t reach statistical significance. The researchers could find no evidence of a heightened...
Source: Science - The Huffington Post - June 8, 2016 Category: Science Source Type: news

ADHD Medication May Boost Kids' Arrhythmia RiskADHD Medication May Boost Kids' Arrhythmia Risk
Children and young people prescribed methylphenidate, commonly used in ADHD, have an increased risk for arrhythmia in the weeks after initiation of treatment. Medscape Medical News (Source: Medscape Psychiatry Headlines)
Source: Medscape Psychiatry Headlines - June 7, 2016 Category: Psychiatry Tags: Psychiatry News Source Type: news

ADHD Meds May Pose Heart Risks for Some Kids
Study found slightly higher chance of irregular heartbeat shortly after starting methylphenidate (Source: WebMD Health)
Source: WebMD Health - June 1, 2016 Category: Consumer Health News Source Type: news

ADHD Meds May Pose Heart Risks for Some Kids
Study found slightly higher chance of irregular heartbeat shortly after starting methylphenidate Source: HealthDay Related MedlinePlus Pages: Attention Deficit Hyperactivity Disorder, Medicines and Children (Source: MedlinePlus Health News)
Source: MedlinePlus Health News - June 1, 2016 Category: Consumer Health News Source Type: news

ADHD drugs 'linked to risk of heart rhythm problems'
Use of methylphenidate in children and young people with attention deficit hyperactivity disorder is linked to an increased risk of arrhythmia shortly after the start of treatment, warn researchers. (Source: Nursing Times)
Source: Nursing Times - June 1, 2016 Category: Nursing Source Type: news

Methylphenidate tied to greater risk of arrhythmia in children, adolescents
Children and adolescents with attention-deficit/hyperactivity disorder who are prescribed methylphenidate to manage their conditions stand at a higher risk for arrhythmia and other, more serious,... (Source: Pediatric News)
Source: Pediatric News - May 31, 2016 Category: Journals (General) Source Type: news

Methylphenidate tied to greater risk of arrhythmia in children, adolescents
Children and adolescents with attention-deficit/hyperactivity disorder who are prescribed methylphenidate to manage their conditions stand at a higher risk for arrhythmia and other, more serious,... (Source: Family Practice News)
Source: Family Practice News - May 31, 2016 Category: Primary Care Source Type: news

Methylphenidate Tied to Increased Arrhythmia Risk in Kids with ADHD (FREE)
By Kelly Young Edited by David G. Fairchild, MD, MPH, and Lorenzo Di Francesco, MD, FACP, FHM Use of methylphenidate in children and adolescents with attention-deficit/hyperactivity disorder (ADHD) is associated with increased risk for arrhythmia — and potentially elevated risk for myocardial infarction — according to a self-controlled case series study in The BMJ. Using a South Korean … (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - May 31, 2016 Category: Primary Care Source Type: news

Quillivant XR (Methylphenidate Hydrochloride Extended Release Oral Suspension, CII ) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - May 25, 2016 Category: Drugs & Pharmacology Source Type: news

Quantifying the benefits and risks of psychostimulant medication for ADHD
Establishing the benefits and possible risks of psychostimulant medication as a treatment for childhood Attention Deficit Hyperactivity Disorder (ADHD) is vital, says Philip Shaw, M.D., Ph.D., a researcher with NHGRI's Social and Behavioral Research Branch. His review of a recent meta-analysis on the use of the psychostimulant methylphenidate for ADHD appeared in the Journal of the American Medical Association (JAMA) and is the subject of a (Source: NHGRI Homepage Highlights)
Source: NHGRI Homepage Highlights - May 9, 2016 Category: Genetics & Stem Cells Source Type: news